CNS Response Inc. has developed a data analysis capability that, when paired with a non-invasive EEG, analyzes a patient’s brain waves and compares those results to a patient outcome database, generating an rEEG report that allows psychiatrists to create personalized medication regimens for the patient.

According to the company, depression costs U.S. employers $83 billion annually; more than half of these costs are associated with treatment-resistant depression. Individuals with treatment-resistant depression cost $8,500 more per year than patients with ordinary depression. Through various studies, rEEG is the first objective, physiology-based, personalized medical technologies proven to efficiently and consistently enable psychiatrists to determine the right treatment for patients.

CNS Response today announced that Charles DeBattista, D.M.H, M.D., will present the results of a recent landmark study of rEEG at the U.S. Psychiatric and Mental Health Congress. The study proved rEEG effective at predicting medication response approximately 65 percent of the time.

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday October 28, 2009

DrStockPick.com Stock Report!

**************************************************************

Cavitation Technologies, Inc. (OTC Bulletin Board: CVAT) has signed Miura Engineering Co., Ltd. Tokyo, Japan (www.miura21.co.jp) as its new agent to serve markets in Japan for CTI’s Nano-Cavitation Process Systems. Miura is a leading Engineering Company specialized in Edible Oil Processing Plants in the Far East.

ANADIGICS, Inc. (NASDAQ: ANAD) today launched a new family of 1GHz hybrid line amplifiers that leverage the Company’s high performance CATV amplifier technology and manufacturing experience to provide exceptional linearity and distortion

CNS Response, Inc. announced that it has received a patent from the U.S. Patent and Trademark Office. The patent, numbered 7,489,964 and titled “Electroencephalography Based Systems and Methods for Selecting Therapies and Predicting Outcomes”, extends application of rEEG® technology to novel methods that can expand indications for CNS pharmaceuticals.

“One of the most compelling opportunities in pharmaceutical marketing is the ability to expand new indications for already approved medications,” commented CNS Response CEO Len Brandt. “With the successful completion of our multisite study for the treatment of resistant depression, I believe we will have demonstrated the utility of the rEEG technology not only to physicians treating behavioral illness, but also to the pharmaceutical industry including ways described in this patent.”

The awarded patent presents novel use of CNS Response protected methodology for development of new indications of FDA approved pharmaceuticals when using an EEG computer analysis. One demonstration of patient